- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT00096473
Efficacy and Safety of Aricept in the Treatment of Severe Alzheimer's Disease
A 24 Week, Multicenter, Randomized, Double-Blind, Placebo-Controlled Evaluation of the Safety and Efficacy of Donepezil Hydrochloride (E2020) in Patients With Severe Alzheimer's Disease Followed by a 12 Week Open-Label Extension Period
Donepezil hydrochloride (Aricept) has been approved to treat symptoms associated with mild to moderate Alzheimer's disease (AD). Aricept has been shown to improve the memory and thinking abilities, activities of daily living and global function in patients. The purpose of the study is to further investigate the effectiveness and safety of donepezil in patients with severe Alzheimer's disease.
Donepezil is thought to work in the brain by increasing the levels of an important brain chemical called acetylcholine. This chemical helps a person's memory to work better.
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
New South Wales
-
Randwick, New South Wales, Australia
-
-
Queensland
-
Brisbane, Queensland, Australia
-
-
South Australia
-
Woodville South, South Australia, Australia
-
-
Victoria
-
Heidelberg West, Victoria, Australia
-
-
Western Australia
-
Nedlands, Western Australia, Australia
-
-
-
-
Ontario
-
Toronto, Ontario, Canada
-
-
-
-
-
Paris, France
- Hôpital Broca-La Rochefoucauld
-
-
-
-
-
Belfast, Ireland
-
-
-
-
-
Bath, United Kingdom
-
Blackpool, United Kingdom
-
Bradford, United Kingdom
-
-
East Sussex
-
St. Leonards on Sea, East Sussex, United Kingdom
-
-
Southampton
-
West End, Southampton, United Kingdom
-
-
Wilshire
-
Swindon, Wilshire, United Kingdom
-
-
-
-
Alabama
-
Northport, Alabama, United States
-
-
Arizona
-
Phoenix, Arizona, United States
-
Sun City, Arizona, United States
-
Tucson, Arizona, United States
-
-
California
-
San Francisco, California, United States
-
Santa Monica, California, United States
-
Torrance, California, United States
-
-
Colorado
-
Denver, Colorado, United States
-
-
Florida
-
Ft. Lauderdale, Florida, United States
-
Ft. Myers, Florida, United States
-
North Miami, Florida, United States
-
St. Petersburg, Florida, United States
-
-
Georgia
-
Atlanta, Georgia, United States
-
-
Illinois
-
Chicago, Illinois, United States
-
-
Louisiana
-
New Orleans, Louisiana, United States
-
-
Massachusetts
-
Springfield, Massachusetts, United States
-
-
New Jersey
-
Long Branch, New Jersey, United States
-
Piscataway, New Jersey, United States
-
-
New York
-
New Hyde Park, New York, United States
-
-
North Carolina
-
Greenville, North Carolina, United States
-
Raleigh, North Carolina, United States
-
-
Ohio
-
Centerville, Ohio, United States
-
-
Oklahoma
-
Oklahoma City, Oklahoma, United States
-
-
Oregon
-
Medford, Oregon, United States
-
Portland, Oregon, United States
-
-
Pennsylvania
-
Jenkintown, Pennsylvania, United States
-
-
Texas
-
Austin, Texas, United States
-
Houston, Texas, United States
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Clinically diagnosed Alzheimer's Disease with MMSE score 1~12
- Have not been treated by any medication for Alzheimer's Disease in past 3 months
- Live in community or Assisted Living Facility
- Healthy or with chronic diseases that are medically controlled or stabilized
- Able to swallow tablets
Exclusion Criteria:
- Any primary neurological or psychiatric diagnosis (including depressive disorder) other than Alzheimer's Disease
- Dementia caused by organic diseases other than Alzheimer's Disease
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
---|
Assessments of global and cognitive function of Severe AD patients
|
Secondary Outcome Measures
Outcome Measure |
---|
Assessment of behavior and performance on Activity of Daily Living in severe AD patients
|
Assessment of caregiver burden
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Study Director: Sharon Richardson, Ph.D., Eisai Inc.
- Study Director: Honglan Li, Ph.D., Eisai Inc.
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
- Mental Disorders
- Brain Diseases
- Central Nervous System Diseases
- Nervous System Diseases
- Neurocognitive Disorders
- Neurodegenerative Diseases
- Tauopathies
- Dementia
- Alzheimer Disease
- Physiological Effects of Drugs
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Cholinergic Agents
- Enzyme Inhibitors
- Nootropic Agents
- Cholinesterase Inhibitors
- Donepezil
Other Study ID Numbers
- E2020-A001-315
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Dementia
-
University of North Carolina, Chapel HillNational Institute on Aging (NIA)CompletedAlzheimer Dementia | Dementia Alzheimers | CaregiverUnited States
-
Temple UniversityRecruitingDementia | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Hebrew SeniorLifeRecruitingAging | Alzheimer Dementia | Presenile Alzheimer DementiaUnited States
-
Temple UniversityRecruitingDementia | Alzheimer Disease | Mild Cognitive Impairment | Dementia, Vascular | Dementia, Mixed | Dementia Alzheimers | Mild Dementia | Dementia of Alzheimer Type | Dementia, MildUnited States
-
Cognito Therapeutics, Inc.Enrolling by invitationExtension to a Pivotal Study of Sensory Stimulation in Alzheimer's Disease (OLE Hope Study, CA-0015)Cognitive Impairment | Alzheimer Disease | Mild Cognitive Impairment | Dementia Alzheimers | Dementia of Alzheimer Type | AD | Dementia, Mild | Dementia ModerateUnited States
-
University College, LondonNot yet recruitingDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal | DEM
-
University College, LondonThe University of Hong KongUnknownDementia | Dementia, Vascular | Dementia, Mixed | Dementia With Lewy Bodies | Dementia of Alzheimer Type | Dementia Moderate | Dementia Severe | Dementia Frontal
-
National Tainan Junior College of NursingCompletedCognitive Impairment | Dementia, Mild | Dementia ModerateTaiwan
-
Karen RobertoNational Institute on Aging (NIA)RecruitingDementia | Dementia Alzheimers | Neuro-Degenerative Disease | Dementia of Alzheimer Type | Dementia SevereUnited States
-
Karolinska InstitutetRegion Stockholm; KTH Royal Institute of TechnologyActive, not recruitingAlzheimer Dementia | Dementia DisordersSweden
Clinical Trials on Donepezil hydrochloride
-
Eisai Co., Ltd.CompletedDementia With Lewy Bodies (DLB)Japan
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States
-
Eisai Inc.PfizerTerminatedCognitive Dysfunction | Down SyndromeUnited States
-
Eisai Inc.CompletedMigraine HeadacheUnited States
-
Teva Pharmaceuticals USACompletedHealthyUnited States
-
Eisai Inc.CompletedMild Cognitive ImpairmentUnited States
-
Teva Pharmaceuticals USACompletedHealthyUnited States
-
Eisai Inc.Eisai LimitedCompleted
-
Stanford UniversityCompleted
-
Shanghai Synergy Pharmaceutical Sciences Co., Ltd.Completed